A series of novel 1,2,3-triazole and chiral Schiff base hybrids 2–6 were synthesized by Schiff base condensation reaction from pre-prepared parent component of the hybrids (1,2,3-triazole 1) and series of primary chiral amines and their chemical structure were confirmed using NMR and FTIR spectroscopies, and CHN elemental analysis. Compounds 1–6 were evaluated for their anticancer activity against two cancer PC3 (prostate) and A375 (skin) and MRC-5 (healthy) cell lines by Almar Blue assay method. The compounds exhibited significant cytotoxicity against the tested cancer cell lines. Among the tested compounds 3 and 6 showed very good activity for the inhibition of the cancer cell lines and low toxicity for the healthy cell lines. All the compounds exhibited high binding affinity for Androgen receptor modulators (PDB ID: 5t8e) and Human MIA (PDB ID: 1i1j) inhibitors compared to the reference anticancer drug (cisplatin). Structure activity relationships (SARs) of the tested compounds is in good agreement with DFT and molecular docking studies. The compounds exhibited desirable physicochemical properties for drug likeness.
Polar substituted Schiff bases and 1,2,3‐triazole hybrids (2–6) were successfully synthesized by Schiff base condensation reaction between the previously synthesized triazole 1 and series of polar substituted amines. The chemical structures of the hybrids were confirmed using spectroscopies (NMR and FTIR), CHN elemental analysis and single‐crystal x‐ray diffraction analysis. The compounds were evaluated for their antiproliferative activity against two cancer cells, PC3 (prostate) and MCF7 (breast) cell lines, using the alamarBlue assay method, and camptothecin was employed as a standard. All the compounds exhibited good activity for the proliferation of the cancer cell lines compared to the standard, and their activity is concentration‐dependent. Compounds 1, 2, 4 and 5 exhibited good caspase activity with relevant dosages that inhibited 50% (IC50) in prostate cancer cells. All the compounds exhibited high binding affinity for human 3‐alpha hydroxysteroid dehydrogenase type 3 (PDB ID: 4xo6) and Androgen receptor (PDB ID: 2Q7K) inhibitors compared to the reference anticancer drug (camptothecin). Structure–activity relationships (SARs) of the tested compounds are in good agreement with DFT and molecular docking studies. ADMET analysis was used to predict the pharmacokinetics, pharmacodynamics and toxicology of the compounds, and it proved that the compounds exhibited desirable physicochemical properties for drug likeness.